Enzymatica Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Public

  • Employees
  • 18

Employees

  • Stock Symbol
  • ENZY

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $0.24
  • (As of Monday Closing)

Enzymatica General Information

Description

Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme oral spray designed to treat and relieve cold and flu-like symptoms by creating a protective barrier against viruses in the upper respiratory tract. The company combines in-house enzyme production in Iceland with international distribution partnerships to drive expansion. Enzymatica currently sells products in Sweden, the UK and Iceland.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Ideon Science Park
  • Scheelevägen 19
  • 223 70 Lund
  • Sweden
+46 046-286
Primary Industry
Other Devices and Supplies
Other Industries
Pharmaceuticals
Stock Exchange
STO
Vertical(s)
Corporate Office
  • Ideon Science Park
  • Scheelevägen 19
  • 223 70 Lund
  • Sweden
+46 046-286

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Enzymatica Stock Performance

As of 16-Nov-2026, Enzymatica’s stock price is $0.24. Its current market cap is $59M with 243M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.24 $0.25 $0.16 - $0.36 $59M 243M 110K -$0.02

Enzymatica Financials Summary

As of 30-Sep-2026, Enzymatica has a trailing 12-month revenue of $5.48M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 41,626 46,748 26,152 66,102
Revenue 5,479 5,486 4,309 4,789
EBITDA (4,292) (4,784) (4,380) (3,901)
Net Income (4,412) (5,282) (5,028) (4,678)
Total Assets 12,349 15,429 17,694 12,599
Total Debt 1,381 111 199 1,809
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Enzymatica Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Enzymatica‘s full profile, request access.

Request a free trial

Enzymatica Patents

Enzymatica Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3749296-A1 Esters of hydroxy-benzoic acids for use in the treatment of rhinovirus Active 07-Feb-2018
EP-3749296-B1 Esters of hydroxy-benzoic acids for use in the treatment of rhinovirus Inactive 07-Feb-2018
US-20210213112-A1 Esters of hydroxy-benzoic acids for use in the treatment of rhinovirus Inactive 07-Feb-2018
WO-2019154937-A1 Esters of hydroxy-benzoic acids for use in the treatment of rhinovirus Inactive 07-Feb-2018
ES-2900661-T3 Hydroxy-benzoic acid esters for use in the treatment of rhinoviruses Active 07-Feb-2018 A61K31/216
To view Enzymatica’s complete patent history, request access »

Enzymatica Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Enzymatica Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Enzymatica‘s full profile, request access.

Request a free trial

Enzymatica Acquisitions (1)

Enzymatica’s most recent deal was a Merger/Acquisition with Zymetech for . The deal was made on 01-Apr-2016.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Zymetech 01-Apr-2016 Merger/Acquisition Pharmaceuticals
To view Enzymatica’s complete acquisitions history, request access »

Enzymatica ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Enzymatica’s complete esg history, request access »

Enzymatica Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Enzymatica Care Lund, Sweden 2006

Enzymatica FAQs

  • When was Enzymatica founded?

    Enzymatica was founded in 2007.

  • Where is Enzymatica headquartered?

    Enzymatica is headquartered in Lund, Sweden.

  • What is the size of Enzymatica?

    Enzymatica has 18 total employees.

  • What industry is Enzymatica in?

    Enzymatica’s primary industry is Other Devices and Supplies.

  • Is Enzymatica a private or public company?

    Enzymatica is a Public company.

  • What is Enzymatica’s stock symbol?

    The ticker symbol for Enzymatica is ENZY.

  • What is the current stock price of Enzymatica?

    As of 16-Nov-2026 the stock price of Enzymatica is $0.24.

  • What is the current market cap of Enzymatica?

    The current market capitalization of Enzymatica is $59M.

  • What is Enzymatica’s current revenue?

    The trailing twelve month revenue for Enzymatica is $5.48M.

  • What is Enzymatica’s annual earnings per share (EPS)?

    Enzymatica’s EPS for 12 months was -$0.02.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process